A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
Status:
Completed
Trial end date:
2009-12-23
Target enrollment:
Participant gender:
Summary
Study of ONTAK and CHOP (chemotherapy drugs) to find out their ability to make Peripheral
T-cell lymphoma disappear (for any period of time) and potentially lengthen life. The study
will also compare what kind of side effects these drugs cause and how often they occur. The
hypothesis is that patients with newly diagnosed peripheral T-Cell lymphoma, when given ONTAK
+ CHOP, will tolerate the treatment and will have a 20% improvement in response rate when
compared to CHOP alone.